Vaccines for preventing herpes zoster in older adults.

BACKGROUND Herpes zoster, also known as 'shingles', is a neurocutaneous disease characterised by the reactivation of the latent varicella zoster virus (VZV), the virus that causes chickenpox when immunity to VZV declines. It is an extremely painful condition that can last many weeks or months and it can significantly compromise the quality of life of affected individuals. The natural process of aging is associated with a reduction in cellular immunity and this predisposes older people to herpes zoster. Vaccination with an attenuated form of VZV activates specific T cell production avoiding viral reactivation. The Food and Drug Administration has approved a herpes zoster vaccine with an attenuated active virus for clinical use among older adults, which has been tested in large populations. A new adjuvanted recombinant VZV subunit zoster vaccine has also been tested. It consists of recombinant VZV glycoprotein E and a liposome-based AS01B adjuvant system. This new vaccine is not yet available for clinical use. OBJECTIVES To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults. SEARCH METHODS For this 2015 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 9), MEDLINE (1948 to the 3rd week of October 2015), EMBASE (2010 to October 2015), CINAHL (1981 to October 2015) and LILACS (1982 to October 2015). SELECTION CRITERIA Randomised controlled trials (RCTs) or quasi-RCTs comparing zoster vaccine with placebo or no vaccine, to prevent herpes zoster in older adults (mean age > 60 years). DATA COLLECTION AND ANALYSIS Two review authors independently collected and analysed data using a data extraction form. They also performed 'Risk of bias' assessment. MAIN RESULTS We identified 13 studies involving 69,916 participants. The largest study included 38,546 participants. All studies were conducted in high-income countries and included only healthy Caucasian individuals ≥ 60 years of age without immunosuppressive comorbidities. Ten studies used live attenuated varicella zoster virus (VZV) vaccines. Three studies tested a new type of vaccine not yet available for clinical use. We judged five of the included studies to be at low risk of bias.The incidence of herpes zoster, at up to three years of follow-up, was lower in participants who received the vaccine than in those who received a placebo: risk ratio (RR) 0.49; 95% confidence interval (CI) 0.43 to 0.56, risk difference (RD) 2%, number needed to treat to benefit (NNTB) 50; GRADE: moderate quality evidence. The vaccinated group had a higher incidence of mild to moderate intensity adverse events. These date came from one large study that included 38,546 people aged 60 years or older.A study including 8122 participants compared the new vaccine (not yet available) to the placebo; the group that received the new vaccine had a lower incidence of herpes zoster at 3.2 years of follow-up: RR 0.04, 95% CI 0.02 to 0.10, RD 3%, NNTB 33; GRADE: moderate quality evidence. The vaccinated group had a higher incidence of adverse events but most them were of mild to moderate intensity.All studies received funding from the pharmaceutical industry. AUTHORS' CONCLUSIONS Herpes zoster vaccine is effective in preventing herpes zoster disease and this protection can last three years. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity.There are studies of a new vaccine (with a VZV glycoproteic fraction plus adjuvant), which is currently not yet available for clinical use.

[1]  R. Whitley,et al.  Clinical practice. Herpes zoster. , 2002, The New England journal of medicine.

[2]  A. Hall,et al.  What does epidemiology tell us about risk factors for herpes zoster? , 2004, The Lancet. Infectious diseases.

[3]  M. Irwin,et al.  Augmenting Immune Responses to Varicella Zoster Virus in Older Adults: A Randomized, Controlled Trial of Tai Chi , 2007, Journal of the American Geriatrics Society.

[4]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[5]  D. Partridge,et al.  The treatment of varicella-zoster virus infection and its complications , 2009, Expert opinion on pharmacotherapy.

[6]  S. Tyring,et al.  Family history as a risk factor for herpes zoster: a case-control study. , 2008, Archives of dermatology.

[7]  Gordon Guyatt,et al.  An emerging consensus on grading recommendations? , 2006, ACP journal club.

[8]  Huseyin Naci,et al.  Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers , 2013, BMC Medicine.

[9]  E. Ledent,et al.  A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. , 2012, The Journal of infectious diseases.

[10]  Lidia Oostvogels,et al.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. , 2016, The New England journal of medicine.

[11]  L. Smeeth,et al.  Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study , 2013, PLoS medicine.

[12]  L. Cámpora,et al.  Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. , 2018, Vaccine.

[13]  G. Icardi,et al.  Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: A randomized study of a single dose vs. two different two-dose schedules , 2013, Human vaccines & immunotherapeutics.

[14]  Y. Shoenfeld,et al.  The new H1N1 and HPV vaccines and old fears , 2010, Current opinion in rheumatology.

[15]  J. Hornberger,et al.  Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults , 2006, Annals of Internal Medicine.

[16]  Jianjun Li,et al.  Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age. , 2007, Vaccine.

[17]  A. Rice,et al.  Postherpetic Neuralgia , 2014 .

[18]  M. Levin,et al.  Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. , 2018, Vaccine.

[19]  R. K. Evans,et al.  Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial. , 2016, The Lancet. Infectious diseases.

[20]  F. Marra,et al.  Increasing incidence associated with herpes zoster infection in British Columbia, Canada , 2016, BMC Infectious Diseases.

[21]  K. Schmader,et al.  Treatment and prevention of postherpetic neuralgia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Sadoff,et al.  Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. , 2007, Vaccine.

[23]  C. Chan,et al.  Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. , 2000, Vaccine.

[24]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[25]  P. Moore,et al.  VZV: pathogenesis and the disease consequences of primary infection -- Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis , 2007 .

[26]  M. Levin,et al.  Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. , 1996, Viral immunology.

[27]  Y. Shoenfeld,et al.  Transverse myelitis and vaccines: a multi-analysis , 2009, Lupus.

[28]  Y. Shoenfeld,et al.  The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld’s syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry , 2018, Clinical Rheumatology.

[29]  R. Cervera,et al.  Catastrophic antiphospholipid (Asherson's) syndrome. , 2006, British journal of hospital medicine.

[30]  Jianjun Li,et al.  Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. , 2012, Vaccine.

[31]  Shinn-Jang Hwang,et al.  Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.

[32]  M. Irwin,et al.  Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. , 2008, The Journal of infectious diseases.

[33]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[34]  K. Kawai,et al.  Systematic review of incidence and complications of herpes zoster: towards a global perspective , 2014, BMJ Open.

[35]  K. Reisinger,et al.  Safety and tolerability of zoster vaccine in adults ≥60 years old , 2011, Human vaccines.

[36]  AL Gruver,et al.  Immunosenescence of ageing , 2007, The Journal of pathology.

[37]  T. Ohkubo,et al.  Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[38]  C. Dantec,et al.  Epigenomic revolution in autoimmune diseases , 2015 .

[39]  T. Heineman,et al.  Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly , 2016, Human vaccines & immunotherapeutics.

[40]  K. Schmader,et al.  Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  C. Kensil,et al.  Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. , 1991, Journal of immunology.

[42]  T. Nurmikko,et al.  Polymorphism of the IL-10 Gene is Associated with Susceptibility to Herpes Zoster , 2002, Scandinavian journal of infectious diseases.

[43]  G. Keating,et al.  Zoster Vaccine (Zostavax®) , 2010, Drugs & aging.

[44]  D J Newell,et al.  Intention-to-treat analysis: implications for quantitative and qualitative research. , 1992, International journal of epidemiology.

[45]  D G Altman,et al.  Indirect comparisons of competing interventions. , 2005, Health technology assessment.

[46]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[47]  P. van Damme,et al.  A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. , 2017, Vaccine.

[48]  Hope-Simpson Re THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. , 1965 .

[49]  E. Trannoy,et al.  A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. , 1998, The Journal of infectious diseases.

[50]  T. Schwarz,et al.  Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older , 2017, The Journal of infectious diseases.

[51]  A. Leplège,et al.  Herpes Zoster Pain, Postherpetic Neuralgia, and Quality of Life in the Elderly , 2011, Pain practice : the official journal of World Institute of Pain.

[52]  E. Trannoy,et al.  Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. , 2000, Vaccine.

[53]  B. Yawn,et al.  Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. , 2016, Clinical Infectious Diseases.

[54]  M. Braun,et al.  Postlicensure safety surveillance for varicella vaccine. , 2000, JAMA.

[55]  K. Schmader,et al.  Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults , 2010, Journal of the American Geriatrics Society.

[56]  J. Y. Huh,et al.  Disease burden of herpes zoster in Korea. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[57]  W. Chung,et al.  The Incidence and Risk of Herpes Zoster in Patients With Sleep Disorders , 2016, Medicine.

[58]  J. García de Lomas,et al.  Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial. , 2015, Vaccine.

[59]  K. Schmader,et al.  The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults , 2007, The Clinical journal of pain.

[60]  Y. Yew,et al.  Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of Adverse Events in a National Database. , 2015, Journal of drugs in dermatology : JDD.

[61]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[62]  A. Arvin Aging, immunity, and the varicella-zoster virus. , 2005, The New England journal of medicine.

[63]  S. Sutradhar,et al.  Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older , 2009, Clinical and Vaccine Immunology.

[64]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. , 2013, Journal of autoimmunity.

[65]  B. Weaver The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States , 2007, The Journal of the American Osteopathic Association.

[66]  E. Riedmann,et al.  Letter from the Editor , 2013, Human vaccines & immunotherapeutics.

[67]  M. Levin,et al.  Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. , 2007, Vaccine.

[68]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[69]  K. Schmader,et al.  Safety of Herpes Zoster Vaccine in the Shingles Prevention Study , 2010, Annals of Internal Medicine.

[70]  K. Schmader,et al.  The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. , 2008, The Journal of infectious diseases.

[71]  David P. Martin,et al.  Herpes zoster (shingles) and postherpetic neuralgia. , 2009, Mayo Clinic proceedings.

[72]  E. Ledent,et al.  Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. , 2013, The Journal of infectious diseases.

[73]  K. Schmader,et al.  A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster , 2009, PAIN®.

[74]  I. D. de Bruijn,et al.  Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. , 2007, Vaccine.

[75]  Ivan S. F. Chan,et al.  A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax , 2007, Clinical and Vaccine Immunology.

[76]  D. Rimland,et al.  Increasing incidence of herpes zoster among Veterans. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  Joanne Benhamu,et al.  Revisiting adverse reactions to vaccines: A critical appraisal of Autoimmune Syndrome Induced by Adjuvants (ASIA). , 2015, Journal of autoimmunity.

[78]  M. Levin,et al.  Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. , 1994, Viral immunology.

[79]  D. Persing,et al.  Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents , 2004, Expert opinion on biological therapy.

[80]  Ivan S F Chan,et al.  Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older , 2007, Journal of the American Geriatrics Society.

[81]  K. Schmader,et al.  Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. , 2009, The Journal of infectious diseases.

[82]  A. Arvin,et al.  Varicella-zoster virus , 1996, Clinical microbiology reviews.

[83]  M. Levin,et al.  Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. , 2010, Vaccine.

[84]  C. Macintyre,et al.  Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old , 2010, Human vaccines.

[85]  C. Grose,et al.  Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. , 1986, Journal of immunology.

[86]  Jae-We Cho,et al.  Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. , 2007, Journal of dermatological science.

[87]  Tzeng-Ji Chen,et al.  Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. , 2009, Acta dermato-venereologica.

[88]  V. Abraira,et al.  [Investigation methods in clinical cardiology. IV. Clinical measurements in cardiology: validity and errors of measurements]. , 1997, Revista espanola de cardiologia.

[89]  R. Cohrs,et al.  Neurologic complications of the reactivation of varicella-zoster virus. , 2000, The New England journal of medicine.

[90]  A. Sabato,et al.  No evidence of family history as a risk factor for herpes zoster in patients with post‐herpetic neuralgia , 2010, Journal of medical virology.

[91]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[92]  T. Spector,et al.  Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts , 2013, PLoS medicine.

[93]  K. Schmader,et al.  Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. , 2004, The journal of pain : official journal of the American Pain Society.

[94]  Manfred S. Green,et al.  Diabetes as a Risk Factor for Herpes Zoster Infection: Results of a Population-Based Study in Israel , 2008, Infection.

[95]  Kenneth J. Smith,et al.  Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  D. Machin,et al.  Intention to treat--who should use ITT? , 1993, British Journal of Cancer.

[97]  R. Dworkin,et al.  Acute pain in herpes zoster and its impact on health-related quality of life. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[98]  J. B. Cabello,et al.  Las mediciones clínicas en cardiología: validez y errores de medición , 1997 .

[99]  R. Epstein,et al.  Herpes zoster and quality of life , 1995, Neurology.

[100]  M. Kicinski Publication Bias in Recent Meta-Analyses , 2013, PloS one.

[101]  Lee Bw Review of varicella zoster seroepidemiology in India and South‐east Asia , 1998 .

[102]  E. Ledent,et al.  Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. , 2014, Vaccine.

[103]  R. Reichman,et al.  Herpes Zoster-Varicella Infections in Immunosuppressed Patients , 1978 .